drugset / Trial / NCT05337254
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
Timeline
- Start
- 2021-03-05
- Primary completion
- 2021-06-04
- Completion
- 2021-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dihydroergotamine | Small molecule | 1 mg | Intranasal |
| Comparator | Dihydroergotamine | Small molecule | 2 mg | Intranasal |
| Comparator | Dihydroergotamine | Small molecule | 5.2 mg | Intranasal |
| Comparator | Dihydroergotamine | Small molecule | 7 mg | Intranasal |
| Comparator | Dihydroergotamine | Small molecule | 8.6 mg | Intranasal |